ICON Public (NASDAQ:ICLR – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $13.90-14.10 for the period, compared to the consensus estimate of $15.08. The company issued revenue guidance of $8.26-8.30 billion, compared to the consensus revenue estimate of $8.51 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.
ICON Public Price Performance
Shares of NASDAQ:ICLR traded down $56.73 during trading on Thursday, reaching $224.03. The company had a trading volume of 4,952,401 shares, compared to its average volume of 604,278. ICON Public has a twelve month low of $223.96 and a twelve month high of $347.72. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. The firm has a market capitalization of $18.48 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. The firm’s fifty day moving average is $301.78 and its 200 day moving average is $311.59.
ICON Public (NASDAQ:ICLR – Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The firm had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the previous year, the business posted $3.10 earnings per share. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, equities analysts forecast that ICON Public will post 14.54 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Analysis on ICON Public
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More
- Five stocks we like better than ICON Public
- Canadian Penny Stocks: Can They Make You Rich?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is an Earnings Surprise?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.